

1 **TITLE: Using a polygenic score to account for genomic risk factors in a model to detect**  
2 **individuals with dilated ascending thoracic aortas**

3  
4 **Authors:** John DePaolo, MD, PhD,<sup>1</sup> Gina Biagetti, MD,<sup>2</sup> Renae Judy, MS,<sup>1</sup> Grace J. Wang,  
5 MD,<sup>2</sup> John Kelly, MD,<sup>3</sup> Amit Iyengar, MD,<sup>3</sup> Nicholas J. Goel, MD,<sup>3</sup> Nimesh Desai, MD, PhD,<sup>3</sup>  
6 Wilson Y. Szeto, MD,<sup>3</sup> Joseph E. Bavaria, MD,<sup>3</sup> Michael G. Levin, MD,<sup>4,5\*</sup> Scott M. Damrauer,  
7 MD,<sup>2,4,5,6\*</sup>

8  
9 **Affiliations:**

10 <sup>1</sup> Department of Surgery, Perelman School of Medicine, University of Pennsylvania,  
11 Philadelphia, PA 19104, USA.

12 <sup>2</sup> Division of Vascular Surgery, Department of Surgery, Perelman School of Medicine,  
13 University of Pennsylvania, Philadelphia, PA 19104, USA.

14 <sup>3</sup> Division of Cardiovascular Surgery, Department of Surgery, Perelman School of Medicine,  
15 University of Pennsylvania, Philadelphia, PA 19104, USA.

16 <sup>4</sup> Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of  
17 Pennsylvania, PA 19104, USA.

18 <sup>5</sup> Corporal Michael Crescenz VA Medical Center, Philadelphia, PA 19104, USA.

19 <sup>6</sup> Department of Genetics, Perelman School of Medicine, University of Pennsylvania,  
20 Philadelphia, PA 19104, USA.

21 \*co-last authors

22  
23  
24 **Brief Title** : Polygenic score inclusion in aortic dilation risk model

25 **Word count** : 3551

26 **References** : 25

27 **Tables** : 2

28 **Figures** : 3

29  
30  
31 **Address for correspondence:**

32 Scott Damrauer, MD

33 Division of Vascular Surgery

34 Hospital of the University of Pennsylvania

35 3400 Spruce Street, 14th Floor South Perelman Center

36 Philadelphia, PA 19104

37 Office: 215-615-1698

38 [scott.damrauer@penmedicine.upenn.edu](mailto:scott.damrauer@penmedicine.upenn.edu)

39

40

41 **Abstract**

42 **Background:**

43 Ascending thoracic aortic dilation is a complex trait that involves modifiable and non-modifiable  
44 risk factors and can lead to thoracic aortic aneurysm and dissection. Clinical risk factors have  
45 been shown to predict ascending thoracic aortic diameter. Polygenic scores (PGS) are  
46 increasingly used to assess clinical risk for multifactorial diseases. The degree to which a PGS  
47 can improve aortic diameter prediction is not known. In this study we tested the extent to which  
48 the addition of a PGS to clinical prediction algorithms improves the prediction of aortic  
49 diameter.

50 **Methods:**

51 The patient cohort comprised 6,790 Penn Medicine Biobank (PMBB) participants with available  
52 echocardiography and clinical data linked to genome-wide genotype data. Linear regression  
53 models were used to integrate PGS weights derived from a large genome wide association  
54 study of thoracic aortic diameter in the UK biobank and were compared to the performance of  
55 the standard and a reweighted variation of the recently published AORTA Score.

56 **Results:**

57 Cohort participants were 56% male, had a median age of 61 years (IQR 52-70) with a mean  
58 ascending aortic diameter of 3.4 cm (SD 0.5). Compared to the AORTA Score which explained  
59 28.4% (95% CI 28.1% to 29.2%) of the variance in aortic diameter, AORTA Score + PGS  
60 explained 28.8%, (95% CI 28.1% to 29.6%), the reweighted AORTA score explained 30.4%  
61 (95% CI 29.6% to 31.2%), and the reweighted AORTA Score + PGS explained 31.0% (95% CI  
62 30.2% to 31.8%). The addition of a PGS to either the AORTA Score or the reweighted AORTA  
63 Score improved model sensitivity for the identifying individuals with a thoracic aortic diameter  $\geq$   
64 4 cm. The respective areas under the receiver operator characteristic curve for the AORTA  
65 Score + PGS (0.771, 95% CI 0.756 to 0.787) and reweighted AORTA Score + PGS (0.785,

66 95% CI 0.770 to 0.800) were greater than the standard AORTA Score (0.767, 95% CI 0.751 to  
67 0.783) and reweighted AORTA Score (0.780 95% CI 0.765 to 0.795).

68 **Conclusions:**

69 We demonstrated that inclusion of a PGS to the AORTA Score results in a small but clinically  
70 meaningful performance enhancement. Further investigation is necessary to determine if  
71 combining genetic and clinical risk prediction improves outcomes for thoracic aortic disease.

72

## 73 **Introduction**

74 Thoracic aortic dilation can lead thoracic aortic aneurysm (TAA) development, a life-  
75 threatening condition. Unimpeded, TAA can progress to acute rupture or acute thoracic aortic  
76 dissection, which represent approximately 8% of all out-of-hospital cardiopulmonary arrests.<sup>1</sup>  
77 For patients admitted to a hospital for emergent treatment of thoracic aortic aneurysm and  
78 dissection (TAAD), observed 30-day mortality is 39-49%.<sup>2-5</sup> Despite the high mortality risk,  
79 most cases of ascending thoracic aortic dilation and subsequent aneurysm development are  
80 asymptomatic and identified incidentally.<sup>6</sup> When recognized, asymptomatic ascending thoracic  
81 aortic aneurysms can be monitored with serial imaging and treated with aggressive blood  
82 pressure control and elective surgery, yielding significantly improved results when compared to  
83 emergency intervention.<sup>7</sup>

84 Across a range of cardiovascular diseases, polygenic scores (PGS) have become  
85 increasingly attractive as predictive tools to utilize in clinical settings to estimate individual level  
86 genetic risk for specific diagnoses.<sup>8-10</sup> We and others have formulated PGSs to assess risk of  
87 increased ascending thoracic aortic diameter,<sup>11,12</sup> and TAAD.<sup>13</sup> GWAS have identified several  
88 genomic loci associated with both ascending thoracic aortic diameter and TAAD, and both  
89 traits are heritable, making PGS potentially useful for identifying individuals with enlarged  
90 aortas; however, the clinical utility of PGS remain poorly understood.

91 Recently, a clinical risk score to identify patients at elevated risk for ascending aortic  
92 dilation, referred to as the AORTA (aorta optimized regression for thoracic aneurysm) Score,  
93 was developed using cardiac magnetic resonance imaging (cMRI) measurements of  
94 ascending thoracic aortic diameter among individuals within the UK Biobank (UKB), and  
95 validated among subsets of individuals within the Framingham Heart Study (using computed  
96 tomography [CT] scans) and Mass General Brigham Biobank (using transthoracic  
97 echocardiography [TTE]).<sup>14</sup> The present study validates the AORTA score within a separate

98 diverse population, demonstrates the importance of creating individual population weighted  
99 values for specific factors in a predictive model, and shows the incremental benefit of including  
100 a PGS as a component of a combined clinical risk tool.

101

## 102 **Methods**

### 103 *Study Population*

104 Penn Medicine Biobank (PMBB) is composed of individuals recruited from across the  
105 Penn Medicine healthcare system. Each participant consents to linkage of electronic health  
106 records to biospecimens. A total of 44,297 volunteers have undergone genotyping per  
107 standard methodology as previously described.<sup>15,16</sup> Among these individuals, 6,790 have at  
108 least one transthoracic echocardiography (TTE) study with a recorded measurement of  
109 ascending thoracic aortic diameter.

### 110 *Clinical Covariate Selection*

111 We utilized the set of clinical factors identified in the original AORTA Score,<sup>14</sup> including  
112 the presence of a diagnosis of hypertension, diabetes, and/or hyperlipidemia, sex, age, body  
113 mass index (BMI), weight, height, systolic and diastolic blood pressure, and pulse rate. We  
114 also included the previously reported series of interaction terms between the 11 clinical  
115 covariates.

### 116 *Prediction model creation*

117 Using the clinical covariates and source code for the AORTA Score model  
118 (<https://github.com/carbocation/genomisc>), we derived predicted ascending thoracic aortic  
119 diameter values for PMBB participants and a linear regression model was fit using measured  
120 ascending thoracic aortic diameter as the dependent variable. The “AORTA Score + PGS”  
121 model was similarly constructed with PGS values included as a covariate for each individual in  
122 the PMBB. PGS scores were derived using weights from a previously published weighted

123 allele PGS of ascending thoracic aortic diameter among UKB participants genetically similar to  
124 the European reference population.<sup>12</sup> This PGS for ascending aortic diameter was constructed  
125 using 89 autosomal independently significant SNPs from individuals genetically similar to the  
126 European reference population in the UKB. Principal components of ancestry were derived for  
127 all PMBB participants and included as covariates in the AORTA Score + PGS model.

128 Three additional comparator models were created to assess the performance of the  
129 both the AORTA Score and the AORTA Score + PGS among PMBB individuals. First, to  
130 improve model performance by leveraging local population health characteristics, a reweighted  
131 version of the AORTA Score with clinical weights derived from individuals within PMBB,  
132 subsequently referred to as the “reweighted AORTA Score,” was created without consideration  
133 of PGS or principal components of ancestry. Second, this model was expanded to include the  
134 PGS plus the first five PCs of ancestry, which is subsequently referred to as the “reweighted  
135 AORTA Score + PGS.” Third, an age plus sex model that included both PGS and the first five  
136 principal components of ancestry, subsequently referred to as the “Age + Sex + PGS model,”  
137 was also analyzed to determine the effect of genetic factors without considering clinical risk  
138 factors.

### 139 *Model evaluation*

140 To limit over-fitting, performance measures are reported using 5 repeats of 10-fold  
141 cross-validation. This repeated cross-validation splits the data evenly 10 times, holds out one  
142 of 10 folds for model assessment while the data across the remaining nine folds are used to fit  
143 the model. This entire process is repeated five times, resulting in 50 separate model fits/tests.  
144 Final resampling estimates of performance average each cross-validated replicate with 95%  
145 credible intervals.

146 Model performance and calibration were evaluated by several methods including *R*-  
147 squared (RSQ) and root-mean-square error (RMSE) using *yardstick* (v1.2.0),<sup>17</sup> linear

148 regression effect estimate (coefficient of the slope of the linear model), and intercept  
149 (calibration). Predicted and residual aortic diameters were plotted against actual  
150 measurements. Bland-Altman plots were created for each individual model.<sup>18</sup>

151 Between-model comparisons were systematically made using Bayesian analysis of  
152 variance (ANOVA) function in the *tidy posterior* package in R (v1.0.0) that relied upon random  
153 intercept modeling to fully account for resampling by assuming that individual resamples only  
154 effect the model by changing the intercept.<sup>19</sup> We generated posterior distributions of RSQ and  
155 RMSE values with corresponding credible intervals to compare individual model performance.  
156 This allowed the derivation of probability that the proportion of the comparative model RSQ  
157 and RMSE posteriors are greater than zero; that is, the probability that the estimated  
158 performance of the two models is different. Posterior distributions were also used to compute  
159 the probability of being practically equivalent or significant with a practical effect size of +/- 2%,  
160 also known as the Region of Practical Equivalence (ROPE) estimate.<sup>20</sup>

#### 161 *Score Thresholding and Confusion Matrix Analysis*

162 A range of score threshold values between three and four were tested in confusion  
163 matrices to assess the appropriate linear model cutoff to optimize sensitivity and specificity and  
164 predict ascending thoracic aortic diameter  $\geq 4$  cm. For each respective linear model, score  
165 threshold values were set at intervals increasing by five percent, representing the fifth percent  
166 highest score to the 50<sup>th</sup> percent highest score. These thresholds were used to identify the  
167 true-positives, false-positives, true-negatives, and false-negatives at any given cutoff value  
168 compared to the actual values, and score sensitivity and specificity were analyzed.

#### 169 *Binary model construction and Decision Curve Analysis*

170 Logistic regression models were used to predict the ascending thoracic aortic diameter  
171  $\geq 4$  cm based on AORTA Score covariates and PGS. To test prediction performance, the area  
172 under the receiver operator characteristic curve (AUROC) was calculated for each model using

173 the *pROC* package in R (v1.18.1).<sup>21</sup> Ninety-five percent confidence intervals for the AUROC  
174 were calculated using the *ci.auc* function.

175 Clinical net benefit was assessed for each logistic regression model using decision  
176 curve analysis, an analytic instrument to test the benefit of a diagnostic tool in the presence of  
177 competing harms and benefits.<sup>22,23</sup> Decision curve analysis was performed on each model with  
178 “net benefit” defined as cases of ascending thoracic aortic diameter  $\geq 4$  cm identified for  
179 screening imaging per 100 individuals. These analyses generate a plot of net benefit as a  
180 function of “threshold probability” at which a clinician or individual considers the potential  
181 benefit versus harm of undergoing TTE imaging. For instance, if a clinician were to say that  
182 there is no harm to unnecessary screening, the “threshold probability” would equal 0%. If,  
183 however, a clinician believed screening represented an unnecessary risk no matter what could  
184 be found on subsequent imaging, the “threshold probability” would equal 100%. TTE imaging  
185 has minimal risks, as it is non-invasive, in-expensive, and has no radiation exposure; therefore,  
186 the threshold probability assessed in this study was 0-25%. Decision curve analysis was  
187 performed using *dcurves* (v0.4.0).<sup>24</sup>

## 188 *Statistical Analyses*

189 Statistical analysis was performed in R version 4.2.1 (R Foundation for Statistical  
190 Computing, Vienna, Austria). The *Tidymodels* R package (v1.0.0) was used for all model  
191 cross-validation analysis.<sup>25</sup> Throughout this investigation, Bayesian statistics were used to  
192 derive posterior probabilities and credible intervals of individual model performance statistics.

193

## 194 **Results**

### 195 *Clinical Characteristics*

196 A total of 6790 PMBB participants were included. Forty-four percent of the individuals  
197 were female, and the median age was 61 years (IQR 52 – 70) [Table 1]. The mean ascending



198 aortic diameter was 3.4 cm, and there were 830 individuals (12%) with an ascending aortic  
199 diameter  $\geq$  4 cm. Seventy-four percent of individuals had a history of hypertension, 63% had a  
200 history of hyperlipidemia, and 33% had a history of diabetes. Compared to the UKB training  
201 cohort from which the AORTA Score was derived, the PMBB cohort had increased prevalence  
202 of co-morbidities and larger average ascending thoracic aortic diameter (**Table 1**).

203

#### 204 *PMBB Model Calibration and Performance*

205 The performance of the standard AORTA Score and each model variation were utilized  
206 to estimate the aortic diameter for each PMBB participant within the cohort. For a 1 cm  
207 estimate for ascending thoracic aortic diameter using the AORTA Score, the measured aortic  
208 diameter was 1.08 cm (95% confidence interval [CI] 1.07 cm to 1.15 cm,  $P < 0.001$ ) suggesting  
209 a significant underestimation of aortic diameter; this was not seen with any of the other models  
210 (**Table S1**). Predicted values for individual models were plotted against measured and residual  
211 values (**Figure S1**). In Bland-Altman plots, the 95% limits of agreement of the AORTA Score  
212 0.63 cm to -1.04 cm, suggesting the model underestimated large diameters more than it  
213 overestimated small diameters, and generally conservative errors (**Figure S2**). Bland-Altman  
214 plots for each of the other comparator models demonstrated more balanced 95% limits of  
215 agreement with consistently conservative errors.

216 Individual model RSQ and RMSE demonstrated that the reweighted AORTA  
217 Score + PGS was the best performing model, and that the addition of PGS conferred a small  
218 performance improvement on both the AORTA Score and the reweighted AORTA Score  
219 (**Table 2**). Compared to the AORTA Score which explained 28.4% (95% CI 28.1% to 29.2%) of  
220 the variance in aortic diameter, AORTA Score + PGS explained 28.8%, (95% CI 28.1% to  
221 29.6%), the reweighted AORTA score explained 30.4% (95% CI 29.6% to 31.2%), and the  
222 reweighted AORTA Score + PGS explained 31.0% (95% CI 30.2% to 31.8%).

223 To determine specific inter-model performance differences, we applied Bayesian  
224 principles to resampled data from PMBB to generate a set of posterior probabilities and  
225 credible intervals (CI) for the RSQ and RMSE of each model for ANOVA analysis between  
226 models.<sup>25</sup> The differences in RSQ between each of AORTA Score versus AORTA Score + PGS  
227 (RSQ mean difference 0.002, 95% CI -0.002 to 0.005) and reweighted AORTA Score versus  
228 reweighted AORTA Score + PGS (RSQ mean difference 0.002, 95% CI -0.001 to 0.006)  
229 suggested that the addition of the PGS to either model incrementally improve explanation of  
230 variance (**Table S2, Figure 1**). Comparable results were observed when investigating direct  
231 comparison of RMSE between these models suggesting PGS also improves model accuracy  
232 (**Table S3, Figure S3**). However, neither marginal improvement was practically different using  
233 a region of practical equivalence (ROPE) of 2% (**Tables S4 and S5**). These results suggest  
234 that the addition of the PGS modestly improves model explanation of variance (RSQ) and  
235 accuracy (RMSE) independent of reweighting in a statistically significant but not clinically  
236 meaningful manner.

237 As the AORTA Score variables are commonly assessed clinically and require no  
238 additional testing, if performance improvements can be made by simple reweighting, a PGS  
239 may not be necessary as it may require additional cost/testing. To assess if the addition of a  
240 PGS to the standard AORTA Score conferred a similar performance improvement compared  
241 as model reweighting, we directly compared AORTA Score + PGS and the reweighted AORTA  
242 Score. The reweighted AORTA Score had superior explanation of variance (RSQ mean  
243 difference 0.016, 95% CI 0.009 to 0.022) and accuracy (RMSE mean difference 0.005, 95% CI  
244 0.002 to 0.008) [**Tables S2 and S3, Figures 1 and S3**]. However, neither difference achieved  
245 likely practical significance (**Table S4 and S5**). These findings suggest that model reweighting  
246 based on local baseline health characteristics improves AORTA Score performance marginally  
247 more than the addition of a PGS.

248

249 *Assessing Model Clinical Utility*

250 To assess the clinical performance of each model in predicting individuals with aortic  
251 diameters  $\geq 4$  cm, a clinically meaningful threshold at which serial imaging would be  
252 recommended, we performed logistic regression analysis using the covariates from the  
253 AORTA score, and PGS where indicated, and analyzed receiver operator characteristic curves  
254 (ROC) and area under the ROC (AUROC) (**Figure 2**). The AORTA Score + PGS (AUROC =  
255 0.771, 95% CI 0.756 to 0.787), reweighted AORTA Score (AUROC = 0.780 95% CI 0.765 to  
256 0.795), and reweighted AORTA Score + PGS (AUROC = 0.785, 95% CI 0.770 to 0.800) each  
257 better predicted ascending thoracic aortic diameter  $\geq 4$  cm compared to the standard AORTA  
258 Score (AUROC = 0.767, 95% CI 0.751 to 0.783) and Age + Sex + PGS (AUROC = 0.737, 95%  
259 CI 0.720 to 0.753). Taken together, these results suggest that the addition of the PGS to the  
260 standard and reweighted AORTA Scores improves the ability of either model to predict aortic  
261 diameter greater than 4 cm, and that the optimal model is the reweighted AORTA Score +  
262 PGS.

263 To investigate whether PGS integration provides net clinical benefit to the AORTA  
264 Score, we performed decision curve analyses (DCA) using each logistic regression model.  
265 DCA allows the assessment of net clinical benefit which equates to the number of true  
266 positives screened less the number of false positives screened at a specific threshold  
267 probability.<sup>22</sup> In this evaluation, the screening test is a transthoracic echocardiogram, a non-  
268 invasive and relatively inexpensive procedure. Using a risk threshold of 0-25%, each of the five  
269 models evaluated performs better than the “Screen All” or “Screen None” strategies (**Table S6**,  
270 **Figure 3**). At the threshold probability of 25% for example, the net benefit of the reweighted  
271 AORTA Score + PGS logistic regression model was 1.5 cases per 100 individuals screened.  
272 This net benefit was increased compared to the reweighted AORTA Score logistic regression

273 (net benefit of 1.4 cases per 100 individuals screened), AORTA Score + PGS logistic  
274 regression (1.4 cases per 100 individuals screened), the standard AORTA Score logistic  
275 regression (1.0 cases per 100 individuals screened), and the Age + Sex + PGS logistic  
276 regression (0.2 cases per 100 individuals screened). These data suggest that the addition of  
277 the PGS and reweighting the AORTA Score based on local clinical risk factors may slightly  
278 enhance the overall clinical utility of the baseline AORTA Score model (approximately 1  
279 additional case per 200 individuals screened), and provides further evidence that the addition  
280 of a PGS incrementally improves model performance.

281 As a sensitivity analysis we constructed confusion matrices using each linear regression  
282 model at different score thresholds and compared model sensitivity and specificity to compare  
283 optimal model thresholds that could result in maximized clinical utility to discern individuals  
284 who would benefit from screening (**Tables S7 and S8**). Thresholds were set every five  
285 percent from the fifth percentile score to the 50<sup>th</sup> percentile score. These scores were then  
286 utilized as cutoff values for predicting a case (ascending thoracic aortic diameter  $\geq 4$  cm)  
287 versus controls. Across thresholds, the reweighted AORTA Score + PGS was consistently the  
288 best performing model; for instance, using the 10<sup>th</sup> percentile score in every model, the  
289 reweighted AORTA Score + PGS had a sensitivity of 29.8% compared to 27.7% for the  
290 reweighted AORTA Score, 27.0% for the AORTA Score + PGS, 26.5% for the AORTA Score,  
291 and 22.4% for the Age + Sex + PGS. The addition of the PGS frequently contributed to  
292 improved model sensitivity supporting our observation that the addition of a PGS incrementally  
293 improves model performance.

294

## 295 **Discussion**

296 Using a published predictive model of enlarged ascending aortic diameter, we  
297 demonstrated that the addition of a PGS based on the largest available GWAS of ascending

298 thoracic aortic diameter modestly improved standard AORTA Score and reweighted AORTA  
299 Score performance by several measures including the explanation of variance (RSQ) and  
300 accuracy (RMSE), however these improvements in performance fell within a range of practical  
301 equivalence of 2%. The addition of PGS also marginally improved the predictive capacity to  
302 identify aortic diameter  $\geq 4$  cm as determined by AUROC, sensitivity, and overall net benefit in  
303 decision curve analyses. Notably, in the sensitivity assessment the addition of the PGS  
304 incrementally improved model performance at a range of thresholds suggesting that the benefit  
305 is not limited to a narrow cohort with elevated risk. We also demonstrated that using PMBB  
306 participant clinical data to reweight the AORTA Score improved model performance more than  
307 the addition of the PGS alone, and that the combination of reweighting and PGS created the  
308 best performing model.

309         Currently, there are no meaningful recommendations for screening individuals for  
310 dilated ascending thoracic aortas who lack a history of familial disease. Our findings are  
311 instructive when considering how to clinically implement a screening model for ascending  
312 thoracic aortic aneurysm. Both the addition of genetic information and reweighting the  
313 covariates improved AORTA Score model fit and corrected aortic diameter underestimation  
314 observed with the standard AORTA Score model in PMBB. Though the predictive  
315 improvement in AORTA Score from the addition of the PGS and/or from reweighting was  
316 marginal, both confusion matrix and decision curve analysis suggest that these changes will  
317 consistently benefit clinical decision-making more than the current strategy (i.e., screen none)  
318 by identifying individuals at risk for aortic dilation who would benefit from a non-invasive TTE.  
319 Furthermore, the addition of the PGS, covariate reweighting, and the combination of both  
320 consistently perform better than the standard AORTA Score within the threshold probability  
321 ranges assessed.

322 AORTA Score covariate reweighting based on local health characteristics easily  
323 aggregable from electronic health record (EHR) platforms may offer a more expedient strategy  
324 for rapid, optimal clinical implementation of AORTA Score as it avoids reliance on genetic data  
325 that are not ubiquitously available. However, in clinical settings where large biobanks have  
326 been established, integration of the PGS and reweighting the AORTA Score would most  
327 successfully identify individuals who warrant screening TTEs. These centers of care may even  
328 consider implementing a program similar to Recall by Genotype (RbG) initiatives where all  
329 enrolled individuals are screened using the AORTA Score + PGS and those at elevated risk  
330 are contacted and offered TTEs. As genetic data becomes increasingly available due to the  
331 rapid speed and availability of whole genome sequencing, integration of a model accounting  
332 for both local health characteristics and genetic data may become more universally applicable  
333 with the potential to more accurately identify individuals who warrant screening.

334 Notably, the modest improvements currently attributable to the PGS are derived from  
335 the largest GWAS available for ascending thoracic aortic diameter. This GWAS included  
336 38,694 individuals, 2-3% of whom had aortic diameters  $\geq 4$  cm. Compared to other more  
337 powerful PGS available in other cardiovascular diseases, this is a relatively small cohort of  
338 individuals from which to derive PGS weights. While ascending thoracic aortic diameter was  
339 found to be highly heritable in this GWAS (63%, 95% CI 60–67),<sup>12</sup> even our best-performing  
340 model explained only a modest proportion of variance in aortic diameter, and substantially less  
341 variability than the anticipated heritability. As GWAS sizes expand and understanding of the  
342 genetic underpinnings of ascending aortic diameter and aneurysmal degeneration improve, the  
343 AORTA Score enhancement attributable to PGS inclusion will likely continue to grow.

344

345 *Limitations*

346 This study has several limitations. First, both the AORTA Score and the PGS for  
347 ascending thoracic aortic dilation were derived from the UK Biobank whose participants are  
348 largely healthier and less diverse than most of the major urban centers within the US from  
349 which regional biobanks like the PMBB are constructed. For instance, not only do PMBB  
350 participants have a larger ascending thoracic aortic diameter to begin with (mean 3.36 cm  
351 compared to 3.18 cm), but the PMBB training cohort had a higher median BMI (29.3 compared  
352 to 25.7), rates of hypertension (73.9% compared to 30.0%), hyperlipidemia (62.9% compared  
353 to 21.3%), and diabetes (32.5% compared to 2.9%). While these factors were considered in  
354 the reweighted AORTA Score, it remains unclear how these health factors would impact  
355 broader implementation of the AORTA Score, and how the underlying genetic risks for these  
356 conditions may impact aortic dilation.

357 Additionally, this study was limited to a single biobank. The effect of the PGS may be  
358 limited as a function of sample size and power. Sensitivity and specificity calculations also  
359 depend highly on disease prevalence, which is relatively elevated compared to UKB. Further  
360 investigation among other cohorts will contribute to assessing the benefit of including the PGS  
361 as a covariate within the AORTA Score.

### 362 *Conclusions*

363 Our findings suggest that the reweighted AORTA score model using PMBB data and  
364 incorporating PGS weights is the best performing linear regression model to predict enlarged  
365 ascending thoracic aortic diameter. Independent of reweighting, the addition of genomic  
366 covariates modestly improved overall performance of the standard AORTA Score and the  
367 reweighted AORTA Score suggesting that utilization of genetic data may enhance clinical  
368 outcomes when determining individuals who warrant screening for ascending thoracic aortic  
369 dilation. Further research is needed to determine if similar cohorts have improved model  
370 performance with the addition of a PGS as a covariate, and whether that improvement

371 translates to better clinical outcomes among a diverse population with differing levels of  
372 baseline health.

373

374 **Acknowledgements**

375 We thank the participants of the Penn Medicine Biobank. The PMBB is supported by Perelman  
376 School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the  
377 National Center for Advancing Translational Sciences of the National Institutes of Health under  
378 CTSA award number UL1TR001878. J.D. is supported by the American Heart Association  
379 (23POST1011251). M.G.L. is supported by the Institute for Translational Medicine and  
380 Therapeutics of the Perelman School of Medicine at the University of Pennsylvania, the  
381 NIH/NHLBI National Research Service Award postdoctoral fellowship (T32HL007843), the  
382 Measey Foundation, and the Doris Duke Foundation. S.M.D. is supported by funding from the  
383 Department of Veterans Affairs Office of Research (IK2-CX001780).

384



385 **References**

- 386 1. Takeuchi S, Yamaguchi Y, Soejima K, Yoshino H. Incidence and characteristics of  
387 acute aortic dissection in patients with out-of-hospital cardiopulmonary arrest evaluated  
388 by non-contrast computed tomography. *Eur Heart J Acute Cardiovasc Care*.  
389 2020;9:S48-S57. doi: 10.1177/2048872620923647
- 390 2. Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM, Oxford  
391 Vascular S. Population-based study of incidence and outcome of acute aortic dissection  
392 and premorbid risk factor control: 10-year results from the Oxford Vascular Study.  
393 *Circulation*. 2013;127:2031-2037. doi: 10.1161/CIRCULATIONAHA.112.000483
- 394 3. Landenhed M, Engstrom G, Gottsater A, Caulfield MP, Hedblad B, Newton-Cheh C,  
395 Melander O, Smith JG. Risk profiles for aortic dissection and ruptured or surgically  
396 treated aneurysms: a prospective cohort study. *J Am Heart Assoc*. 2015;4:e001513.  
397 doi: 10.1161/JAHA.114.001513
- 398 4. Melvinsdottir IH, Lund SH, Agnarsson BA, Sigvaldason K, Gudbjartsson T, Geirsson A.  
399 The incidence and mortality of acute thoracic aortic dissection: results from a whole  
400 nation study. *Eur J Cardiothorac Surg*. 2016;50:1111-1117. doi: 10.1093/ejcts/ezw235
- 401 5. Trimarchi S, Nienaber CA, Rampoldi V, Myrmet T, Suzuki T, Mehta RH, Bossone E,  
402 Cooper JV, Smith DE, Menicanti L, et al. Contemporary results of surgery in acute type  
403 A aortic dissection: The International Registry of Acute Aortic Dissection experience. *J*  
404 *Thorac Cardiovasc Surg*. 2005;129:112-122. doi: 10.1016/j.jtcvs.2004.09.005
- 405 6. Vilacosta I, San Roman JA, di Bartolomeo R, Eagle K, Estrera AL, Ferrera C, Kaji S,  
406 Nienaber CA, Riambau V, Schafers HJ, et al. Acute Aortic Syndrome Revisited: JACC  
407 State-of-the-Art Review. *J Am Coll Cardiol*. 2021;78:2106-2125. doi:  
408 10.1016/j.jacc.2021.09.022

- 409 7. Wallen T, Habbertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, Yerokun B,  
410 Thibault D, Milewski K, Desai N, et al. Elective Aortic Root Replacement in North  
411 America: Analysis of STS Adult Cardiac Surgery Database. *Ann Thorac Surg.*  
412 2019;107:1307-1312. doi: 10.1016/j.athoracsur.2018.12.039
- 413 8. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander  
414 ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic scores for common  
415 diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet.*  
416 2018;50:1219-1224. doi: 10.1038/s41588-018-0183-z
- 417 9. O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA,  
418 O'Donnell CJ, Willer CJ, Natarajan P, American Heart Association Council on G, et al.  
419 Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the  
420 American Heart Association. *Circulation.* 2022;146:e93-e118. doi:  
421 10.1161/CIR.0000000000001077
- 422 10. Sud A, Horton RH, Hingorani AD, Tzoulaki I, Turnbull C, Houlston RS, Lucassen A.  
423 Realistic expectations are key to realising the benefits of polygenic scores. *BMJ.*  
424 2023;380:e073149. doi: 10.1136/bmj-2022-073149
- 425 11. Tcheandjieu C, Xiao K, Tejeda H, Lynch JA, Ruotsalainen S, Bellomo T, Palnati M,  
426 Judy R, Klarin D, Kember RL, et al. High heritability of ascending aortic diameter and  
427 trans-ancestry prediction of thoracic aortic disease. *Nat Genet.* 2022;54:772-782. doi:  
428 10.1038/s41588-022-01070-7
- 429 12. Pirruccello JP, Chaffin MD, Chou EL, Fleming SJ, Lin H, Nekoui M, Khurshid S,  
430 Friedman SF, Bick AG, Arduini A, et al. Deep learning enables genetic analysis of the  
431 human thoracic aorta. *Nat Genet.* 2022;54:40-51. doi: 10.1038/s41588-021-00962-4

- 432 13. Derek Klarin PD, Anoop Sendamarai et al. Genome-wide Association Study of Thoracic  
433 Aortic Aneurysm and Dissection in the Million Veteran Program. *PREPRINT (Version 1)*  
434 *available at Research Square*. 2022. doi: <https://doi.org/10.21203/rs.3.rs-1507463/v1>
- 435 14. Pirruccello JP, Lin H, Khurshid S, Nekoui M, Weng LC, Vasan RS, Isselbacher EM,  
436 Benjamin EJ, Lubitz SA, Lindsay ME, Ellinor PT. Development of a Prediction Model for  
437 Ascending Aortic Diameter Among Asymptomatic Individuals. *JAMA*. 2022;328:1935-  
438 1944. doi: 10.1001/jama.2022.19701
- 439 15. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, Van Hout CV,  
440 Habegger L, Buckler D, Lai KM, et al. Inactivating Variants in ANGPTL4 and Risk of  
441 Coronary Artery Disease. *N Engl J Med*. 2016;374:1123-1133. doi:  
442 10.1056/NEJMoa1510926
- 443 16. Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, Sirugo G, Kember  
444 RL, Drivas TG, Dudek SM, et al. The Penn Medicine BioBank: Towards a Genomics-  
445 Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse  
446 Population. *J Pers Med*. 2022;12. doi: 10.3390/jpm12121974
- 447 17. Hvitfeldt MKaDVaE. yardstick: Tidy Characterizations of Model Performance. 2023.
- 448 18. Bland JM, Altman DG. Statistical methods for assessing agreement between two  
449 methods of clinical measurement. *Lancet*. 1986;1:307-310.
- 450 19. Kuhn M. tidyposterior: Bayesian Analysis to Compare Models using Resampling  
451 Statistics. 2022.
- 452 20. Kruschke JK, Liddell TM. The Bayesian New Statistics: Hypothesis testing, estimation,  
453 meta-analysis, and power analysis from a Bayesian perspective. *Psychon Bull Rev*.  
454 2018;25:178-206. doi: 10.3758/s13423-016-1221-4

- 455 21. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an  
456 open-source package for R and S+ to analyze and compare ROC curves. *BMC*  
457 *Bioinformatics*. 2011;12:77. doi: 10.1186/1471-2105-12-77
- 458 22. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting  
459 decision curve analysis. *Diagn Progn Res*. 2019;3:18. doi: 10.1186/s41512-019-0064-7
- 460 23. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction  
461 models. *Med Decis Making*. 2006;26:565-574. doi: 10.1177/0272989X06295361
- 462 24. Sjoberg DD. dcurves: Decision Curve Analysis for Model Evaluation. 2022.
- 463 25. Kuhn MW, H. Tidymodels: a collection of packages for modeling and machine learning  
464 using tidyverse principles. 2020.
- 465

466 **Figure Legends**

467

468 **Figure 1. Between-model comparison of difference in explanation of variance (RSQ).**

469 Cross-validated posterior distribution for the difference in RSQ between (A) standard AORTA  
470 Score and AORTA Score + PGS; (B) reweighted AORTA Score and reweighted AORTA Score  
471 + PGS; (C) AORTA Score + PGS and reweighted AORTA Score; (D) standard AORTA Score  
472 and reweighted AORTA Score + PGS. Between-model mean difference and 95% credible  
473 intervals (CIs) in top right corner of each plot. PGS = polygenic score; AS = AORTA Score;  
474 RSQ = *R*-squared.

475

476 **Figure 2. Logistic model receiver operator characteristic curve (ROC) and area under**

477 **the ROC curve to predict ascending thoracic aortic diameter  $\geq 4$  cm.** A) Receiver operator  
478 characteristic curve (ROC) for each of the five models analyzed in the PMBB cohort. B) Area  
479 under the ROC curves with error bars demonstrating 95% confidence intervals. PGS =  
480 polygenic score; AS = AORTA Score.

481

482 **Figure 3: Individual model decision curve analysis.** Decision curve analysis demonstrated

483 clinical net benefit for each model plotted against threshold probability with units representing  
484 cases identified per individual screened at a specific threshold probability using a range of 0-  
485 50%. Results are compared to a model that would screen all individuals (“Screen All”) or  
486 screen no one (“Screen None”). PGS = polygenic score; AS = AORTA Score.

487

488 **Tables**

489 **Table 1.** Clinical characteristics of Penn Medicine Biobank individuals compared to the UKB  
 490 training cohort. UKB training dataset data taken from Pirruccello, et al.<sup>14</sup>

<b>UK Biobank and Penn Medicine Biobank Participant Characteristics</b>			
		UKB Training Dataset	PMBB Dataset
		(N = 30,018)	(N = 6790)
Sex, N (%)	Female	15635 (52.1)	2990 (44.0)
	Male	14383 (47.9)	3800 (56.0)
Ancestry, N (%)	European		4448 (65.5)
	African		2116 (31.2)
	Other		226 (3.3)
Age in years, median (IQR)		65.1 (58.6-70.6)	61.0 (52.3-69.7)
Medical history, N (%)	Hypertension	9009 (30.0)	5013 (73.8)
	Hyperlipidemia	6380 (21.3)	4252 (62.6)
	Diabetes	876 (2.9)	2204 (32.5)
Weight in kg, median (IQR)		74.0 (64.7-84.2)	87.0 (73.6-100.5)
Height in cm, median (IQR)		169 (162-176)	172 (164.0-180.0)
BMI, median (IQR)		25.7 (23.4-28.5)	29.3 (25.2-33.5)
HR in beats/ minute, median (IQR)		67.6 (61.0-75.0)	77.0 (69.8-84.2)
Blood pressure in mmHg, median (IQR)	Systolic	138 (127-150)	127.8 (119.9-135.8)
	Diastolic	78.5 (72.2-85.0)	73.9 (69.2-78.7)
Ascending Aortic Diameter in cm	Mean (SD)	3.18 (0.35)	3.37 (0.50)
	Median (IQR)	3.15 (2.93-3.40)	3.3 (2.95-3.65)
Aortic diameter 4+ cm, N (%)		696 (2.3)	830 (12.2)

492 **Table 2:** R-squared (RSQ) and Root-Mean-Square Error (RMSE) with 95% CI for each model  
493 variation based on 5 repeats of 10-fold cross-validation analysis.


Model RSQ and RMSE		
Model	RSQ (95% CI)	RMSE (95% CI)
AORTA Score	0.284 (0.276 to 0.292)	0.426 (0.423 to 0.430)
AORTA Score + PGS	0.288 (0.281 to 0.296)	0.425 (0.421 to 0.429)
Reweghted AORTA Score	0.304 (0.296 to 0.312)	0.420 (0.417 to 0.424)
Reweghted AORTA Score + PGS	0.310 (0.302 to 0.318)	0.419 (0.415 to 0.422)
Age + Sex + PGS	0.225 (0.216 to 0.234)	0.444 ( 0.440 to o.448)

494

495 CI = Credible Interval; PGS = polygenic score.

496 **Figures**

497 **Figure 1. Between-model comparison of difference in explanation of variance (RSQ).**




498




499 **Figure 2. Logistic model receiver operator characteristic curve (ROC) and area under**  
500 **the ROC curve to predict ascending thoracic aortic diameter  $\geq 4$  cm.**

501



502

503 **Figure 3: Individual model decision curve analysis.**



504